破裂性腹主动脉瘤EVAR可行性评估的观察者间一致性研究
本研究让16名血管外科医生在模拟急诊环境下基于CTA评估20例破裂性腹主动脉瘤(rAAA)患者的EVAR可行性,并与专家团队共识评估比较。结果显示医生间一致性仅为轻微(Cohen's kappa=0.13),观察者间变异度为一般(Fleiss' kappa=0.28,95%CI 0.24-0.32),中位决策时间仅2分26秒。
要点
- 血管外科医生在急诊环境下评估rAAA的EVAR可行性时,与专家共识的一致性仅为轻微(kappa=0.13)。
- 观察者间变异度为一般(Fleiss' kappa=0.28,95%CI 0.24-0.32)。
- 中位决策时间仅2分26秒(IQR 2分10秒),可能不足以完成全面评估。
核心结论
- 血管外科医生在评估复杂解剖rAAA患者的EVAR可行性时共识度极低,决策时间显著短暂。
研究设计与样本
- 16名血管外科医生在模拟急诊环境下基于CTA评估20例rAAA患者的EVAR可行性,并与专家团队在择期环境下使用中心腔线生成软件、无时间压力、遵循IFU的共识评估进行比较。
主要发现
- 20例rAAA中,专家团队认为10例(50%)适合EVAR。
- 医生与专家团队在EVAR可行性上的一致性为轻微(Cohen's kappa=0.13,IQR 0.25)。
- 中位12例(60%)中医生选择了与专家团队相同的治疗方式。
- 观察者间一致性为一般(Fleiss' kappa=0.28,95%CI 0.24-0.32)。
- 中位决策时间为2分26秒(IQR 2分10秒)。
关键数值与推荐
- 专家团队共识评估基于中心腔线生成软件、无时间压力、遵循内移植物IFU。
- EVAR可行性一致性Cohen's kappa=0.13(IQR 0.25)。
- 观察者间一致性Fleiss' kappa=0.28(95%CI 0.24-0.32)。
- 中位决策时间2分26秒(IQR 2分10秒)。
- 主体支架尺寸一致性中位2例(33%,IQR 1)。
临床怎么用
- 在复杂rAAA急诊EVAR可行性评估中,应给予更充分的评估时间以减少观察者间变异。
- 建议采用多学科团队决策、AI辅助工具(如中心腔线生成软件)及更高临床经验以改善一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was designed to investigate agreement between vascular surgeons and expert team consensus assessment, and inter-observer variability for endovascular aneurysm repair (EVAR) feasibility in patients with a ruptured abdominal aortic aneurysm (rAAA) on computed tomography angiography (CTA). METHODS: Sixteen vascular surgeons assessed EVAR feasibility in 20 rAAA patients based on CTA. The majority of patients had rAAA with challenging anatomy. Surgeons were observed, and time to treatment decision (EVAR or open surgical repair [OSR]) was monitored to mimic an acute setting. Reference measurements were determined by an expert team consensus assessment in an elective setting using central luminal line-generating software without time pressure, following the instructions for use (IFU) of the endografts available to the participants. Primary outcomes were: (1) agreement between vascular surgeons in the simulated emergency setting and the expert team on feasibility of EVAR and (2) time to decision on treatment by the 16 surgeons. RESULTS: Out of 20 rAAA cases, 10 (50%) were deemed feasible for EVAR according to the expert team. There was slight agreement between surgeons and the expert team on feasibility for EVAR (Cohen's kappa = 0.13, interquartile range [IQR] 0.25). In a median of 12 rAAA (60%) cases, surgeons chose the same treatment as the expert team. Interobserver variability comparing observers with each other was fair (Fleiss' kappa = 0.28, 95% CI, 0.24-0.32). Median time to treatment decision was 2 minutes and 26 seconds (IQR 2 minutes and 10 seconds). Agreement on main body endograft size between individual surgeons and the expert team occurred in a median of 2 (33%, IQR 1) cases. In 16 (80%) of the cases, EVAR was deemed the preferred treatment option, irrespective of IFU according to the expert team. CONCLUSION: Vascular surgeons showed minimal consensus when assessing the feasibility of EVAR for patients with rAAA with a challenging anatomy using CTA. The time taken to decide upon EVAR feasibility was notably brief.Clinical ImpactIn patients with ruptured abdominal aortic aneurysms and complex anatomy, vascular surgeons showed limited agreement when assessing EVAR feasibility using CTA compared with reference measurements determined by an expert team consensus assessment, and considerable interobserver variability. Agreement on main body endograft choice was low. Median time to treatment decision was 2 min and 26 s. Granting additional time for comprehensive assessment of EVAR feasibility, multidisciplinary team-decision making, the use of AI-supported tools such as CLL generating software, and higher levels of clinical experience in complex rAAA cases might improve interobserver agreement in both future research and clinical context.
引用
- Hoebink M, Aalbregt E, Salman S, et al. Interobserver Agreement on Assessing Endovascular Aneurysm Repair Feasibility in Patients With Ruptured Abdominal Aortic Aneurysms Using Computed Tomography Angiography. J Endovasc Ther. 2026. PMID: 42639753. doi:10.1177/15266028261479537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。